| Autor: |
Kelmendi, Fatos M., Morina, Arsim A., Mekaj, Agon Y., Dragusha, Shefki, Ahmeti, Feti, Alimehmeti, Ridvan, Morina, Qamile, Berisha, Murat, Krasniqi, Blerim, Kerolli, Berat |
| Předmět: |
|
| Zdroj: |
British Journal of Neurosurgery; Feb2023, Vol. 37 Issue 1, p53-58, 6p, 4 Charts, 4 Graphs |
| Abstrakt: |
Among children who sustain mild traumatic brain injury (mTBI), 10–30% develop a cluster of cognitive, physical, and emotional symptoms commonly referred to as post-concussion syndrome (PCS). Symptoms typically resolve within 7–10 days, but a minority of patients report symptoms that persist for months or even years. The aim of our study was to identify a neurobiochemical marker after mTBI that can predict the presence of post-concussion syndrome three months after head injury in paediatric patients. Children between 7 and 16 years of age who had head trauma and no other complaints were included. Three months after the initial visit, participants or parents/guardians were interviewed in person about the children's PCS symptoms using the Rivermead Post-Concussion Symptoms Questionnaire (RPQ). The mean value of S100B protein in serum in 38 patients without signs of PCS was 0.266 μg L−1, with a 95% confidence interval (CI) of 0.221 − 0.310 μg L−1. Among the 22 patients with signs of PCS, the mean value of S100B protein in serum was 0.845 μg L−1, with a 95% CI of 0.745–0.945 μg L−1. Patients with signs of PCS had higher S100B protein levels than those without signs of PCS (p < 0.0001). Our prospective study showed that S100B protein is a useful neurobiomarker for detecting paediatric patients at risk for post-concussion syndrome. We found that the biomarker S100B correlated with the severity of traumatic brain injury (number of lesions on CT) and the presence of post-concussion syndrome. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
